GSK
GSK
701 hedge funds and large institutions have $13.1B invested in GSK in 2014 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 337 increasing their positions, 217 reducing their positions, and 58 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 337 | Existing positions reduced: 217
45% more call options, than puts
Call options by funds: $210M | Put options by funds: $145M
0.26% less ownership
Funds ownership: 4.67% → 4.41% (-0.26%)
3% less funds holding
Funds holding: 722 → 701 (-21)
14% less capital invested
Capital invested by funds: $15.2B → $13.1B (-$2.11B)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
31% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$287M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$170M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$156M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$60.2M |
| 5 |
Morgan Stanley
New York
|
+$59.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$1.06B |
| 2 |
FMI
Fiduciary Management Inc
Milwaukee,
Wisconsin
|
-$315M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$108M |
| 4 |
Renaissance Technologies
New York
|
-$100M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$90.1M |
GSK Hedge Fund Activity: Q3 2014 in Review
701 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2014, worth a combined $13.1B — down 14% from $15.2B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of GSK and 40 opened new positions — a net loss of 18 holders — while 217 trimmed existing stakes and 337 added.
The largest buyer was Hotchkis & Wiley Capital Management, adding an estimated $287M. The largest seller was Dodge & Cox, cutting an estimated $1.06B.
- 701 institutional investors held GSK (GSK) as of Q3 2014, down from 722 in Q2 2014.
- Funds reported $13.1B of GSK stock for Q3 2014, down 14% quarter-over-quarter.
- 40 funds opened new GSK positions in Q3 2014 and 58 closed out, a net change of -18 holders.
- The largest GSK buyer in Q3 2014 was Hotchkis & Wiley Capital Management, an estimated $287M added.
- The largest GSK seller in Q3 2014 was Dodge & Cox, an estimated $1.06B sold.
Based on aggregated 13F filings for Q3 2014.